Scienture Holdings (SCNX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Sep, 2026Executive summary
Annual meeting scheduled for October 28, 2026, to be held virtually, with record date set as September 11, 2026.
Shareholders will vote on four key proposals: election of directors, auditor ratification, executive compensation (say-on-pay), and potential adjournment.
Proxy materials are available online, with multiple voting methods including internet, phone, mail, and virtual attendance.
Voting matters and shareholder proposals
Proposal 1: Election of five directors for one-year terms; nominees are Mayur Doshi, Donald G. Fell, Shankar Hariharan, Subbarao Jayanthi, and Narasimhan Mani.
Proposal 2: Ratification of CM3 Advisory as independent auditor for fiscal year ending December 31, 2026.
Proposal 3: Non-binding advisory vote on executive compensation (say-on-pay).
Proposal 4: Approval to adjourn the meeting if necessary to solicit additional proxies.
No cumulative voting rights; appraisal or dissenters' rights are not applicable.
Board of directors and corporate governance
Board consists of five directors, majority of whom are independent; independence determined per Nasdaq and SEC rules.
Three standing committees: audit, compensation, and nominating/corporate governance, each chaired by an independent director.
Committee charters and governance documents are available on the company website.
Board and committees meet regularly, with executive sessions held without management.
Stockholders can communicate directly with the board.
Latest events from Scienture Holdings
- Q2 2026 revenue surged 510% on ARBLI™ sales, with net loss narrowing and strong liquidity maintained.SCNX
Q2 2026 - Two FDA-approved launches and a robust pipeline drive revenue growth and near-term profitability.SCNX
WTR Insights Conference: Powered by The Small Cap Showcase - Revenue fell sharply in Q3 2024 as the company shifted focus to pharma R&D and paid large dividends.SCNX
Q3 2024 - Specialty pharma pivot with high R&D spend, ongoing losses, and up to $50M ELOC funding planned.SCNX
Registration filing - Biopharma pivots to CNS/CVS drugs, seeks $50M equity, faces losses, dilution, and regulatory risk.SCNX
Registration filing - Clinical-stage pharma seeks $50M equity to fund pipeline amid ongoing losses and high risk.SCNX
Registration filing - Q3 2025 revenue soared 810% on SCN-102 launch, but net loss and liquidity risks persist.SCNX
Q3 2025 - Acquisition of Scienture LLC and asset sales drove 2024 results, but liquidity remains a key risk.SCNX
Q4 2024 - Specialty pharma pivot funded by $50M equity line, with dilution and market risks highlighted.SCNX
Registration filing